| Q34987777 | ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage |
| Q36722804 | Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice |
| Q34053479 | Activation of Hif1α by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity |
| Q37372449 | An inducible long noncoding RNA amplifies DNA damage signaling. |
| Q52820544 | An oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo. |
| Q35869745 | Autophagy confers DNA damage repair pathways to protect the hematopoietic system from nuclear radiation injury |
| Q33896849 | Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death |
| Q64915932 | Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice. |
| Q48278280 | Bone marrow sinusoidal endothelium: damage and potential regeneration following cancer radiotherapy or chemotherapy. |
| Q39185185 | CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage |
| Q36130084 | CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy |
| Q37575488 | CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. |
| Q35635267 | Catalase inhibits ionizing radiation-induced apoptosis in hematopoietic stem and progenitor cells |
| Q92592825 | Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy |
| Q37693690 | Cell cycle proteins as promising targets in cancer therapy |
| Q38728850 | Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. |
| Q91345318 | Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer |
| Q26782637 | Chromatin perturbations during the DNA damage response in higher eukaryotes |
| Q28242623 | Cyclin D as a therapeutic target in cancer |
| Q37798827 | Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors |
| Q51919465 | Dentofacial parameters explaining variability in retroclination of the maxillary central incisors. |
| Q28834064 | Disruption of Notch signaling aggravates irradiation-induced bone marrow injury, which is ameliorated by a soluble Dll1 ligand through Csf2rb2 upregulation |
| Q36394640 | Does CDKN2A loss predict palbociclib benefit? |
| Q38869603 | Emerging targets for radioprotection and radiosensitization in radiotherapy |
| Q39836171 | Enhanced Megakaryopoiesis and Platelet Activity in Hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-Deficient Mice |
| Q90246026 | Epithelial Cell Cycle Behaviour in the Injured Kidney |
| Q34541922 | Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.). |
| Q35221682 | Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents |
| Q21183971 | Genetics and genomics of radiotherapy toxicity: towards prediction |
| Q38866877 | HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles. |
| Q39675064 | HSC senescence upon irradiation |
| Q28731776 | HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates |
| Q26865273 | Hematopoietic stem cell niche maintenance during homeostasis and regeneration |
| Q46581912 | Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors |
| Q30371457 | Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay |
| Q58795413 | Immune mechanisms in the different phases of acute tubular necrosis |
| Q37395807 | Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice |
| Q38760366 | Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth |
| Q38200606 | Intestinal stem cell injury and protection during cancer therapy |
| Q35082713 | Ionizing irradiation induces acute haematopoietic syndrome and gastrointestinal syndrome independently in mice |
| Q27022997 | Linking traumatic brain injury to chronic traumatic encephalopathy: identification of potential mechanisms leading to neurofibrillary tangle development |
| Q35781547 | MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. |
| Q57106504 | Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer |
| Q35549264 | Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions |
| Q28548371 | Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility |
| Q35842970 | Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy |
| Q90024802 | Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial |
| Q37524270 | NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. |
| Q37160539 | New paradigms and future challenges in radiation oncology: an update of biological targets and technology |
| Q35958082 | Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
| Q39638408 | Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). |
| Q38577715 | Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer |
| Q34027724 | Palbociclib: an evidence-based review of its potential in the treatment of breast cancer |
| Q30409339 | Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death |
| Q24617126 | Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity |
| Q28588864 | Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells |
| Q35140111 | Pleiotrophin mediates hematopoietic regeneration via activation of RAS. |
| Q38832541 | Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors |
| Q26770944 | Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome |
| Q38544737 | RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy |
| Q38196712 | Radioprotection of normal tissue cells |
| Q37767574 | Radioprotection: smart games with death |
| Q38710560 | Radioprotective Agents: Strategies and Translational Advances. |
| Q37801346 | Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. |
| Q35586823 | Runx1 loss minimally impacts long-term hematopoietic stem cells |
| Q64064501 | Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials |
| Q38365768 | Searching for targets for the systemic therapy of mesothelioma. |
| Q38218129 | Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. |
| Q37006942 | Sodium orthovanadate (vanadate), a potent mitigator of radiation-induced damage to the hematopoietic system in mice |
| Q47662195 | Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. |
| Q28082912 | Targeting CDK4 and CDK6: From Discovery to Therapy |
| Q26865765 | Targeting cancer with kinase inhibitors |
| Q49547342 | Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer |
| Q33816106 | Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions |
| Q28069910 | Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers |
| Q35056773 | The evolving role of radiation therapy in the management of malignant melanoma |
| Q26865888 | The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis |
| Q34999987 | The transcription factor E74-like factor controls quiescence of endothelial cells and their resistance to myeloablative treatments in bone marrow |
| Q33621603 | Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner |
| Q35182633 | Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer |
| Q48227806 | Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion |
| Q37885468 | Transport processes of radiopharmaceuticals and -modulators. |
| Q34988091 | Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. |
| Q36234051 | Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells |
| Q44274584 | mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. |